<DOC>
	<DOCNO>NCT01223898</DOCNO>
	<brief_summary>This study evaluate effect multiple dos nilotinib pharmacokinetics metabolism midazolam ( sensitive CYP3A probe ) CML patient . The following extension study evaluate safety nilotinib .</brief_summary>
	<brief_title>To Evaluate Effects Multiple Doses Nilotinib Pharmacokinetics Metabolism Midazolam CML Patients With Additional Extension Phase Evaluate Safety Nilotinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Patients cytopathologically confirm diagnosis Ph+ CML Philadelphia chromosome negative ( Ph ) CML patient accelerate chronic phase resistant and/or intolerant least one prior therapy BCRABL tyrosine kinase inhibitor 2 . Female male ≥ 18 year age 3 . Patients nilotinib naïve study entry , e.g . receive nilotinib treatment prior study 4. WHO Performance Status ≤ 2 1 . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) . 2 . Impaired cardiac function 3 . History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis . 4 . Patients actively receive therapy prohibit comedications ( CYP3A4 inhibitor inducer , CYP2C inducer ) 5 . Patients currently receive treatment medication potential prolong QT interval 6 . Treatment immunotherapy chemotherapy within 3 day ( 6 week nitrosurea mitomycinC ) prior Day 1 recover side effect therapy . 7 . Treatment imatinib within 1 week prior Day 1 recover side effect therapy . 8 . Patients hypersensitivity midazolam related compound Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CML ,</keyword>
	<keyword>nilotinib ,</keyword>
	<keyword>midazolam</keyword>
</DOC>